Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

226 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Reply to comment on 'An increase in tumor-infiltrating lymphocytes after treatment is significantly associated with a poor response to neoadjuvant endocrine therapy for estrogen receptor-positive/HER2-negative breast cancers' by Fukui et al.
Fukui R, Watanabe T, Morimoto K, Fujimoto Y, Nagahashi M, Ishikawa E, Hirota S, Miyoshi Y. Fukui R, et al. Among authors: nagahashi m. Breast Cancer. 2024 May;31(3):536-538. doi: 10.1007/s12282-024-01552-y. Epub 2024 Mar 4. Breast Cancer. 2024. PMID: 38433180 No abstract available.
Actionable gene alterations in an Asian population with triple-negative breast cancer.
Nagahashi M, Ling Y, Hayashida T, Kitagawa Y, Futamura M, Yoshida K, Kuwayama T, Nakamura S, Toshikawa C, Yamauchi H, Yamauchi T, Kaneko K, Kanbayashi C, Sato N, Miyoshi Y, Tsuchida J, Nakajima M, Shimada Y, Ichikawa H, Lyle S, Takabe K, Okuda S, Wakai T. Nagahashi M, et al. JCO Precis Oncol. 2018;2:PO.17.00211. doi: 10.1200/po.17.00211. Epub 2018 Jul 23. JCO Precis Oncol. 2018. PMID: 32529167 Free PMC article.
Low intratumoral genetic neutrophil-to-lymphocyte ratio (NLR) is associated with favorable tumor immune microenvironment and with survival in triple negative breast cancer (TNBC).
Tokumaru Y, Oshi M, Murthy V, Tian W, Yan L, Angarita FA, Nagahashi M, Matsuhashi N, Futamura M, Yoshida K, Miyoshi Y, Takabe K. Tokumaru Y, et al. Among authors: nagahashi m. Am J Cancer Res. 2021 Nov 15;11(11):5743-5755. eCollection 2021. Am J Cancer Res. 2021. PMID: 34873491 Free PMC article.
Clinicopathological features of male patients with breast cancer based on a nationwide registry database in Japan.
Shimomura A, Nagahashi M, Kumamaru H, Aogi K, Asaga S, Hayashi N, Iijima K, Kadoya T, Kojima Y, Kubo M, Miyashita M, Miyata H, Niikura N, Ogo E, Tamura K, Tanakura K, Yoshida M, Yamamoto Y, Imoto S, Jinno H. Shimomura A, et al. Among authors: nagahashi m. Breast Cancer. 2022 Nov;29(6):985-992. doi: 10.1007/s12282-022-01378-6. Epub 2022 Jun 22. Breast Cancer. 2022. PMID: 35733033 Free PMC article.
Absolute Lymphocyte Count Is an Independent Prognostic Factor for ER-positive HER2-negative Advanced Breast Cancer Patients Treated With CDK4/6 Inhibitors.
Kanaoka H, Nagahashi M, Atake Y, Hattori A, Bun A, Fukui R, Ozawa H, Fujimoto Y, Higuchi T, Natori K, Imamura M, Murase K, Takatsuka Y, Miyoshi Y. Kanaoka H, et al. Among authors: nagahashi m. Anticancer Res. 2022 Oct;42(10):4867-4878. doi: 10.21873/anticanres.15992. Anticancer Res. 2022. PMID: 36192009
Characteristics of female breast cancer in japan: annual report of the National Clinical Database in 2018.
Tada K, Kumamaru H, Miyata H, Asaga S, Iijima K, Ogo E, Kadoya T, Kubo M, Kojima Y, Tanakura K, Tamura K, Nagahashi M, Niikura N, Hayashi N, Miyashita M, Yoshida M, Ohno S, Imoto S, Jinno H. Tada K, et al. Among authors: nagahashi m. Breast Cancer. 2023 Mar;30(2):157-166. doi: 10.1007/s12282-022-01423-4. Epub 2022 Dec 22. Breast Cancer. 2023. PMID: 36547868 Free PMC article.
Copy number alteration is an independent prognostic biomarker in triple-negative breast cancer patients.
Nagahashi M, Ling Y, Toshikawa C, Hayashida T, Kitagawa Y, Futamura M, Kuwayama T, Nakamura S, Yamauchi H, Yamauchi T, Kaneko K, Kanbayashi C, Sato N, Tsuchida J, Moro K, Nakajima M, Shimada Y, Ichikawa H, Lyle S, Miyoshi Y, Takabe K, Okuda S, Wakai T. Nagahashi M, et al. Breast Cancer. 2023 Jul;30(4):584-595. doi: 10.1007/s12282-023-01449-2. Epub 2023 Mar 17. Breast Cancer. 2023. PMID: 36930419
An increase in tumor-infiltrating lymphocytes after treatment is significantly associated with a poor response to neoadjuvant endocrine therapy for estrogen receptor-positive/HER2-negative breast cancers.
Fukui R, Watanabe T, Morimoto K, Fujimoto Y, Nagahashi M, Ishikawa E, Hirota S, Miyoshi Y. Fukui R, et al. Among authors: nagahashi m. Breast Cancer. 2023 Sep;30(5):703-713. doi: 10.1007/s12282-023-01462-5. Epub 2023 Apr 28. Breast Cancer. 2023. PMID: 37115435 Free PMC article.
226 results